CA2335409C - Appareil et methode pour la preparation de plasma - Google Patents

Appareil et methode pour la preparation de plasma Download PDF

Info

Publication number: CA2335409C
Authority: CA; Canada
Prior art keywords: sample; container; plasma; blood; anticoagulant
Prior art date: 1997-04-30
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

CA002335409A

Other languages

English (en)

Other versions

CA2335409A1 (fr

Inventor

Richard J. Carroll

Frank A. Augello

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Becton Dickinson and Co

Original Assignee

Becton Dickinson and Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-04-30

Filing date

1997-12-02

Publication date

2002-07-02

1997-09-09 Priority claimed from US08/925,851 external-priority patent/US5906744A/en

1997-12-02 Application filed by Becton Dickinson and Co filed Critical Becton Dickinson and Co

1998-10-30 Publication of CA2335409A1 publication Critical patent/CA2335409A1/fr

2002-07-02 Application granted granted Critical

2002-07-02 Publication of CA2335409C publication Critical patent/CA2335409C/fr

2017-12-02 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

238000000034 method Methods 0.000 title claims description 15
238000002360 preparation method Methods 0.000 title abstract description 6
239000003146 anticoagulant agent Substances 0.000 claims abstract description 40
229940127219 anticoagulant drug Drugs 0.000 claims abstract description 40
230000009974 thixotropic effect Effects 0.000 claims abstract description 8
210000004369 blood Anatomy 0.000 claims description 40
239000008280 blood Substances 0.000 claims description 40
210000004027 cell Anatomy 0.000 claims description 9
210000003743 erythrocyte Anatomy 0.000 claims description 6
238000000926 separation method Methods 0.000 claims description 5
239000007921 spray Substances 0.000 claims description 5
230000015271 coagulation Effects 0.000 claims description 3
238000005345 coagulation Methods 0.000 claims description 3
210000000265 leukocyte Anatomy 0.000 claims description 3
238000002955 isolation Methods 0.000 claims description 2
238000002156 mixing Methods 0.000 claims description 2
239000000203 mixture Substances 0.000 abstract description 34
238000009472 formulation Methods 0.000 abstract description 30
150000007523 nucleic acids Chemical class 0.000 abstract description 16
238000012360 testing method Methods 0.000 abstract description 16
108020004707 nucleic acids Proteins 0.000 abstract description 14
102000039446 nucleic acids Human genes 0.000 abstract description 14
230000003321 amplification Effects 0.000 abstract description 13
238000003199 nucleic acid amplification method Methods 0.000 abstract description 13
238000003752 polymerase chain reaction Methods 0.000 abstract description 10
238000005516 engineering process Methods 0.000 abstract description 7
239000007788 liquid Substances 0.000 abstract description 3
238000003556 assay Methods 0.000 abstract description 2
210000002381 plasma Anatomy 0.000 description 33
230000003612 virological effect Effects 0.000 description 14
241000725303 Human immunodeficiency virus Species 0.000 description 10
206010053567 Coagulopathies Diseases 0.000 description 5
230000035602 clotting Effects 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
108020004414 DNA Proteins 0.000 description 4
230000001413 cellular effect Effects 0.000 description 4
239000000463 material Substances 0.000 description 4
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
238000005119 centrifugation Methods 0.000 description 3
208000015181 infectious disease Diseases 0.000 description 3
239000003595 mist Substances 0.000 description 3
238000012544 monitoring process Methods 0.000 description 3
210000000440 neutrophil Anatomy 0.000 description 3
230000008569 process Effects 0.000 description 3
238000005507 spraying Methods 0.000 description 3
206010018910 Haemolysis Diseases 0.000 description 2
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
102000003896 Myeloperoxidases Human genes 0.000 description 2
108090000235 Myeloperoxidases Proteins 0.000 description 2
108091028043 Nucleic acid sequence Proteins 0.000 description 2
238000012408 PCR amplification Methods 0.000 description 2
239000000654 additive Substances 0.000 description 2
230000004888 barrier function Effects 0.000 description 2
230000008901 benefit Effects 0.000 description 2
230000023555 blood coagulation Effects 0.000 description 2
210000001772 blood platelet Anatomy 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
238000000576 coating method Methods 0.000 description 2
238000011109 contamination Methods 0.000 description 2
238000006731 degradation reaction Methods 0.000 description 2
238000001514 detection method Methods 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
JFROQFOCFOKDKU-UHFFFAOYSA-L dipotassium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate;hydron;dihydrate Chemical compound O.O.[K+].[K+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O JFROQFOCFOKDKU-UHFFFAOYSA-L 0.000 description 2
QLBHNVFOQLIYTH-UHFFFAOYSA-L dipotassium;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [K+].[K+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O QLBHNVFOQLIYTH-UHFFFAOYSA-L 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
239000011521 glass Substances 0.000 description 2
230000008588 hemolysis Effects 0.000 description 2
229960002897 heparin Drugs 0.000 description 2
229920000669 heparin Polymers 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
239000004033 plastic Substances 0.000 description 2
229920003023 plastic Polymers 0.000 description 2
229920000728 polyester Polymers 0.000 description 2
-1 polyethylene terephthalate Polymers 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
239000000243 solution Substances 0.000 description 2
XINQFOMFQFGGCQ-UHFFFAOYSA-L (2-dodecoxy-2-oxoethyl)-[6-[(2-dodecoxy-2-oxoethyl)-dimethylazaniumyl]hexyl]-dimethylazanium;dichloride Chemical compound [Cl-].[Cl-].CCCCCCCCCCCCOC(=O)C[N+](C)(C)CCCCCC[N+](C)(C)CC(=O)OCCCCCCCCCCCC XINQFOMFQFGGCQ-UHFFFAOYSA-L 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
208000031886 HIV Infections Diseases 0.000 description 1
208000037357 HIV infectious disease Diseases 0.000 description 1
102000001554 Hemoglobins Human genes 0.000 description 1
108010054147 Hemoglobins Proteins 0.000 description 1
241000711549 Hepacivirus C Species 0.000 description 1
239000004743 Polypropylene Substances 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical class O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
108020000999 Viral RNA Proteins 0.000 description 1
230000002730 additional effect Effects 0.000 description 1
230000002411 adverse Effects 0.000 description 1
238000012801 analytical assay Methods 0.000 description 1
230000002429 anti-coagulating effect Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
210000000601 blood cell Anatomy 0.000 description 1
238000010523 cascade reaction Methods 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
229940000425 combination drug Drugs 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
238000000151 deposition Methods 0.000 description 1
239000004205 dimethyl polysiloxane Substances 0.000 description 1
235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
238000006073 displacement reaction Methods 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
238000002651 drug therapy Methods 0.000 description 1
238000001035 drying Methods 0.000 description 1
230000008014 freezing Effects 0.000 description 1
238000007710 freezing Methods 0.000 description 1
239000008187 granular material Substances 0.000 description 1
230000005484 gravity Effects 0.000 description 1
150000003278 haem Chemical class 0.000 description 1
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
239000012678 infectious agent Substances 0.000 description 1
239000003550 marker Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000011987 methylation Effects 0.000 description 1
238000007069 methylation reaction Methods 0.000 description 1
239000002547 new drug Substances 0.000 description 1
239000002245 particle Substances 0.000 description 1
229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
229920000139 polyethylene terephthalate Polymers 0.000 description 1
239000005020 polyethylene terephthalate Substances 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
229920001155 polypropylene Polymers 0.000 description 1
229920001296 polysiloxane Polymers 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
238000011002 quantification Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000010076 replication Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
230000004044 response Effects 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
229920002545 silicone oil Polymers 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
MAPFUJCWRWFQIY-UHFFFAOYSA-K tripotassium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxymethyl)amino]acetate;dihydrate Chemical compound O.O.[K+].[K+].[K+].OC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O MAPFUJCWRWFQIY-UHFFFAOYSA-K 0.000 description 1

Landscapes

Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Investigating Or Analysing Biological Materials (AREA)

CA002335409A 1997-04-30 1997-12-02 Appareil et methode pour la preparation de plasma Expired - Lifetime CA2335409C (fr)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US4519397P	1997-04-30	1997-04-30
US60/045,193		1997-04-30
US08/925,851		1997-09-09
US08/925,851 US5906744A (en)	1997-04-30	1997-09-09	Tube for preparing a plasma specimen for diagnostic assays and method of making thereof
CA002223165A CA2223165C (fr)	1997-04-30	1997-12-02	Appareil et methode pour la preparation de plasma

Related Parent Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002223165A Division CA2223165C (fr)	1997-04-30	1997-12-02	Appareil et methode pour la preparation de plasma

Publications (2)

Publication Number	Publication Date
CA2335409A1 CA2335409A1 (fr)	1998-10-30
CA2335409C true CA2335409C (fr)	2002-07-02

Family

ID=27170558

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002335409A Expired - Lifetime CA2335409C (fr)	1997-04-30	1997-12-02	Appareil et methode pour la preparation de plasma

Country Status (1)

Country	Link
CA (1)	CA2335409C (fr)

1997
- 1997-12-02 CA CA002335409A patent/CA2335409C/fr not_active Expired - Lifetime

Also Published As

Publication number	Publication date
CA2335409A1 (fr)	1998-10-30

Legal Events

Date	Code	Title	Description
2001-02-22	EEER	Examination request
2018-02-05	MKEX	Expiry	Effective date: 20171204

Publication	Publication Date	Title
US5906744A (en)	1999-05-25	Tube for preparing a plasma specimen for diagnostic assays and method of making thereof
JP2680778B2 (ja)	1997-11-19	凝固阻止溶液およびそれを用いた分離器具と分離法
JP2514783B2 (ja)	1996-07-10	一元的血液凝固活性化物質を有する管およびその製法
CN100515568C (zh)	2009-07-22	收集生物流体样品及处理选定成分的装置和方法
CA2182367C (fr)	2002-07-09	Milieu de gradient de densite pour la separation de cellules
CA2185398C (fr)	1999-11-23	Dispositif de collecte du sang permettant la separation du plasma; methode connexe
US4698311A (en)	1987-10-06	Particle washing and separation method
JP2866803B2 (ja)	1999-03-08	採血管用二経路凝血促進剤
JPH0830703B2 (ja)	1996-03-27	表面加工した採血チューブ
EP0696643B1 (fr)	2004-05-19	Appareil pour inhiber le glycolyse dans des échantillons de sang
CA2335409C (fr)	2002-07-02	Appareil et methode pour la preparation de plasma
JPH09222427A (ja)	1997-08-26	血液検査容器
JP4104710B2 (ja)	2008-06-18	血漿試料を調製するための装置と方法
MXPA97009953A (en)	1999-01-11	Apparatus and method for the preparation of pla
JP2749289B2 (ja)	1998-05-13	採血装置
JP3495106B2 (ja)	2004-02-09	血液成分付着防止剤、血液検査用容器および血液成分付着防止性担体
JPH02277460A (ja)	1990-11-14	採液管
JPS59187263A (ja)	1984-10-24	血液分離管
JPH08292190A (ja)	1996-11-05	血液検査容器